Allarity Therapeutics wins Japan patent for stenoparib DRP companion diagnostic
ALLR•Japan patent extends DRP companion diagnostic protection
Allarity Therapeutics won a Japanese patent covering its DRP companion diagnostic for stenoparib, extending protection in Japan to 2039.
The patent covers gene-expression methods to predict clinical benefit from stenoparib, supporting patient selection in development programs.
The company cited prior DRP patent protection in the U.S. through April 2042, with additional coverage in parts of Europe and Australia.
